ApoE4 Function in Alzheimer's Disease

Overview

This experiment investigates how Apolipoprotein E4 (ApoE4) confers increased AD risk at the cellular level. ApoE4 is the strongest genetic risk factor for late-onset AD, with one copy increasing risk ~3x and two copies ~12x. The mechanism by which ApoE4 increases AD risk remains incompletely understood.

Pathway / Mechanism Diagram

graph TD
    A["APOE Gene"] --> B["APOE e2 (Protective)"]
    A --> C["APOE e3 (Neutral)"]
    A --> D["APOE e4 (Risk Factor)"]
    D --> E["Impaired Abeta Clearance"]
    D --> F["Enhanced Tau Phosphorylation"]
    D --> G["BBB Dysfunction"]
    D --> H["Reduced Lipid Transport"]
    E --> I["Amyloid Accumulation"]
    F --> J["Tangle Formation"]
    G --> K["Neuroinflammation"]
    H --> L["Impaired Synaptic Repair"]
    I --> M["Neurodegeneration"]
    J --> M
    K --> M
    L --> M
    B --> N["Enhanced Abeta Clearance"]
    N --> O["Reduced AD Risk"]
    style D fill:#ef5350,color:#e0e0e0
    style B fill:#1b5e20,color:#e0e0e0
    style M fill:#ef5350,color:#e0e0e0

Research Question

AD Gap #17: How does ApoE4 confer risk at the cellular level?

What are the cellular mechanisms by which ApoE4 promotes Aβ aggregation, neuroinflammation, and neurodegeneration, and can these be therapeutically targeted?

Hypothesis

ApoE4 promotes AD pathogenesis through multiple mechanisms: enhanced Aβ binding and aggregation seeding, impaired Aβ clearance across the BBB, gain of neurotoxic lipoproteins, and amplified neuroinflammation via microglial dysregulation. Targeting these mechanisms will reduce AD risk in ApoE4 carriers.

Experimental Design

Model System

In vitro: Astrocyte and neuron cultures from ApoE4-TR and ApoE3-TR iPSC lines
Animal: ApoE knock-in mice (ApoE3/E3, ApoE3/E4, ApoE4/E4)
Human: ApoE4 carrier vs non-carrier iPSC-derived brain cells

Validation Protocol

Phase 1: ApoE4-Aβ Interaction Mapping

Recombinant ApoE3 vs ApoE4 protein purification (lipidated and non-lipidated)
Surface plasmon resonance (SPR) for Aβ binding affinity (Kd)
Aβ seeding assay: ApoE4-Aβ complexes as seeds for native Aβ aggregation
BBB model: ApoE4 vs ApoE3 astrocytes in transwell with brain endothelial cells

Phase 2: Cellular Mechanisms

RNA-seq of ApoE3 vs ApoE4 astrocytes: identify differentially expressed lipid metabolism and inflammation genes
Lipidomics: characterize ApoE4-associated lipoprotein particles
Phagocytosis assay: microglial uptake of ApoE4-opsonized Aβ
Cytotoxicity assay: neuron death with ApoE4 vs ApoE3 treatment

Phase 3: In Vivo Validation

ApoE4-KI mice with conditional knockout of synaptic ApoE4 expression
Longitudinal PET for amyloid and neuroinflammation (TSPO PET)
Cognitive testing at 6, 12, 18 months
Single-nucleus RNA-seq of brain at endpoint

Phase 4: Therapeutic Targeting

ApoE4 structure correctors (e.g., CN-19) in vivo
Gene therapy: AAV-mediated ApoE3 expression in ApoE4 mice
Small molecule modulators of ApoE lipidation

Expected Outcomes

Quantify Aβ binding enhancement: ApoE4 shows 2-3x higher Aβ binding than ApoE3
Identify novel ApoE4-dependent pathways: Lipid metabolism and inflammation networks
Validate ApoE4 correctors: Demonstrating reduction of neurotoxicity

Feasibility Assessment

Factor	Rating	Notes
Technical feasibility	8/10	iPSC and mouse models well-established; ApoE4-KI mice available
Cost efficiency	7/10	Standard assays; gene therapy adds cost
Timeline	18 months	Phases 1-2 (6 mo) + in vivo (9 mo) + therapy (6 mo)
Cross-disease value	8/10	Relevance to other ApoE-associated conditions

Cost Estimate

Component	Cost (USD)
Personnel (3 FTE × 18 mo)	$450,000
iPSC differentiation and characterization	$120,000
ApoE4-KI mice (200)	$80,000
RNA-seq and lipidomics	$100,000
PET imaging	$60,000
ApoE4 correctors	$40,000
Total	$850,000

Key References

Score

Total Score: 75 (Rank 68)

Dimension	Score
Mechanistic Impact	9
Cure Proximity	7
Feasibility	7
Cost Efficiency	7
Timeline	6
Cross-Disease Value	8
Biomarker Enablement	6
Combinability	7
De-risking Value	8
Novelty	6